Article Text

PDF
Letter
The role of hepatokines in NAFLD-related extrahepatic diseases: culprit or accomplice?
  1. Ri-Yue Jiang1,
  2. Ling Yang2
  1. 1Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
  2. 2Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
  1. Correspondence to Dr Ling Yang, Department of Cardiology, The Third Affiliated Hospital of Soochow University, No. 185 Juqian Street, Changzhou 213003, China; czyangling{at}sina.cn

Statistics from Altmetric.com

We recently read with great interest a review by Adams et al1 showing that non-alcoholic fatty liver disease (NAFLD) has a profound impact on the onset of extrahepatic diseases, such as cardiovascular diseases and kidney diseases. We fully agree with this conclusion, and the authors have fully elucidated the relationship between NAFLD and extrahepatic diseases. We think that hepatokines produced and secreted by liver may play a critical role in NAFLD-related extrahepatic diseases, which would deepen the understanding of this disease.

Fibroblast growth factor 21 (FGF21), a hepatokine that is mainly secreted by the liver, has beneficial effects for improving metabolic …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles